Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.

Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Powles T, Donskov F, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, McHenry MB, Lee CW, McCarthy J, Ejzykowicz F, Tannir NM

Open source

DOI: 10.1002/cncr.34180
Published: 2022 Jun 1
Container: Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cncr.34180,
  title = {Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.},
  author = {Motzer RJ and McDermott DF and Escudier B and Burotto M and Choueiri TK and Hammers HJ and Barthélémy P and Plimack ER and Porta C and George S and Powles T and Donskov F and Gurney H and Kollmannsberger CK and Grimm MO and Barrios C and Tomita Y and Castellano D and Grünwald V and Rini BI and McHenry MB and Lee CW and McCarthy J and Ejzykowicz F and Tannir NM},
  year = {2022},
  journal = {Cancer},
  doi = {10.1002/cncr.34180},
  url = {https://doi.org/10.1002/cncr.34180}
}

RIS

TY  - JOUR
TI  - Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
AU  - Motzer RJ
AU  - McDermott DF
AU  - Escudier B
AU  - Burotto M
AU  - Choueiri TK
AU  - Hammers HJ
AU  - Barthélémy P
AU  - Plimack ER
AU  - Porta C
AU  - George S
AU  - Powles T
AU  - Donskov F
AU  - Gurney H
AU  - Kollmannsberger CK
AU  - Grimm MO
AU  - Barrios C
AU  - Tomita Y
AU  - Castellano D
AU  - Grünwald V
AU  - Rini BI
AU  - McHenry MB
AU  - Lee CW
AU  - McCarthy J
AU  - Ejzykowicz F
AU  - Tannir NM
PY  - 2022
JO  - Cancer
DO  - 10.1002/cncr.34180
UR  - https://doi.org/10.1002/cncr.34180
ER  -

APA

RJ, M., DF, M., B, E., M, B., TK, C., HJ, H., P, B., ER, P., C, P., S, G., T, P., F, D., H, G., CK, K., MO, G., C, B., Y, T., D, C., V, G., BI, R., MB, M., CW, L., J, M., F, E., & NM, T. (2022). Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.. Cancer. https://doi.org/10.1002/cncr.34180

Source records

pubmed · retrieved 2026-09-27T12:40:27.389Z